Max Kullberg
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Molecular Biology top 10%
- Extracellular vesicles in disease
- RNA Interference and Gene Delivery
- Advanced biosensing and bioanalysis techniques
- Circular RNAs in diseases
Papers in ⓘ
-
- RNA Interference and Gene Delivery 10
-
- Immunotherapy and Immune Responses 6
- Co-authors
- Thomas J. Anchordoquy (6 shared papers)Noeen Malik (1 shared paper)Tyson Smyth (1 shared paper)Michael W. Graner (1 shared paper)Peter Smith‐Jones (1 shared paper)Kristine Mann (11 shared papers)Charles W. Gorodetzky (3 shared papers)O. N. Hinsvark (1 shared paper)
- Journals
- Journal of Chromatography A (4 papers)Journal of Pharmaceutical Sciences (3 papers)Nanomedicine Nanotechnology Biology and Medicine (3 papers)Journal of drug targeting (3 papers)Clinical Pharmacology & Therapeutics (2 papers)
- Partner nations
- United StatesBulgariaGermany
In The Last Decade
Max Kullberg
30 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Cancer Research 362
- Molecular Biology 796
- Biomaterials 146
- Toxicology 34
- Immunology 143
Countries citing papers authored by Max Kullberg
This map shows the geographic impact of Max Kullberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Kullberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Kullberg more than expected).
Fields of papers citing papers by Max Kullberg
This network shows the impact of papers produced by Max Kullberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Kullberg. The network helps show where Max Kullberg may publish in the future.
Co-authors
The 19 scholars most cited alongside Max Kullberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Biodistribution and delivery efficiency of unmodified tumor-derived exosomes Hit paper breakdown → | 2014 | 600 |
| 2 | 1984 | 82 | |
| 3 | 2013 | 39 | |
| 4 | 2012 | 35 | |
| 5 | 1974 | 33 | |
| 6 | 2010 | 29 | |
| 7 | 2015 | 26 | |
| 8 | 2004 | 25 | |
| 9 | 2008 | 25 | |
| 10 | 2017 | 23 | |
| 11 | 1974 | 23 | |
| 12 | 2021 | 22 | |
| 13 | 2013 | 21 | |
| 14 | 1980 | 21 | |
| 15 | 1973 | 20 | |
| 16 | 1973 | 20 | |
| 17 | 1980 | 18 | |
| 18 | 2018 | 15 | |
| 19 | 2014 | 11 | |
| 20 | 2016 | 11 |
About Max Kullberg
Max Kullberg is a scholar working on Molecular Biology, Immunology, Analytical Chemistry, Toxicology and Spectroscopy, having authored 31 papers that have together received 1.1k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (10 papers), Immunotherapy and Immune Responses (6 papers), Analytical Chemistry and Chromatography (5 papers), Analytical Methods in Pharmaceuticals (4 papers), Forensic Toxicology and Drug Analysis (4 papers), Nanoparticle-Based Drug Delivery (3 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Cancer Research (362 citations), Molecular Biology (796 citations), Biomaterials (146 citations), Toxicology (34 citations) and Immunology (143 citations). Max Kullberg has collaborated with scholars based in United States, Bulgaria and Germany. Frequent co-authors include Thomas J. Anchordoquy, Noeen Malik, Tyson Smyth, Michael W. Graner, Peter Smith‐Jones, Kristine Mann, Charles W. Gorodetzky, O. N. Hinsvark, Ryan L. McCarthy and Jerome Edelson. Their work appears in journals such as Journal of Chromatography A, Journal of Pharmaceutical Sciences, Nanomedicine Nanotechnology Biology and Medicine, Journal of drug targeting and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.